Osimertinib

The Basics

What is Osimertinib?

Used as a first treatment for a certain type of nonsmall-cell lung cancer (NSCLC) that has spread to other parts of the body.

Brand names for Osimertinib

Osimertinib

How Osimertinib is classified

Antineoplastic Agents, Enzyme Inhibitors, Protein Kinase Inhibitors, Signal Transduction Inhibitors

Osimertinib During Pregnancy

Osimertinib pregnancy category

Category N/ANote that the FDA has deprecated the use of pregnancy categories, so for some medications, this information isn’t available. We still think it’s useful to list historical info, however, given what a common proxy this has been in the past.

What we know about taking Osimertinib while pregnant

N/A

Taking Osimertinib While Breastfeeding

What are recommendations for lactation if you're taking Osimertinib?

No information is available on the clinical use of osimertinib during breastfeeding. Because osimertinib is 95% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 48 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during osimertinib therapy and for 2 weeks after the final dose.

Maternal / infant drug levels

No information is available on the clinical use of osimertinib during breastfeeding. Because osimertinib is 95% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 48 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during osimertinib therapy and for 2 weeks after the final dose.

Possible effects of Osimertinib on milk supply

Relevant published information was not found as of the revision date.

Possible alternatives to Osimertinib

None listed